Clinical study on coronary intervention combined with guanxinning tablets in treatment of acute coronary syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054242

Enrollment

Unknown

Registered

2021-12-11

Start date

2021-12-10

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

Conventional treatment group:Antiplatelet drugs, lipid-lowering drugs, ß-blockers, ACEIs (Angiotesion Converting Enzyme Inhibito), etc.

Intensive treatment group:Conventional treatment + Guanxinning Tablets

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Men and women aged 18-75 years; 2. ACS patients with clear diagnosis (typical chest pain, dynamic electrocardiogram changes or positive troponin); 3. PCI treatment.

Exclusion criteria

Exclusion criteria: 1. Patients unwilling to sign informed consent; 2. History of severe liver, lung, kidney and brain diseases; 3. Hematopoietic system diseases; 4. Drug allergy in this study; 5. Severe infection; 6. Malignant tumor; 7. Mental illnesses; 8. Poor compliance.

Design outcomes

Primary

Measure	Time frame
Times of angina pectoris;Angina pectoris duration;	—

Secondary

Measure	Time frame
Serum hypersensitivity C-reactive protein;Tumor necrosis factor-a;Interleukin-6;Troponin T;	—

Countries

China

Contacts

Public ContactXie Mingbin

Hangzhou Red Cross Hospital

Xiemingbin194@126.com+86 15257120756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026